Protons can be transported across a biological membrane by the proton pump, an essential membrane protein. Mechanisms are based on the Q cycle or conformational changes in the protein structure. The proton pump uses energy during cell respiration to move protons from the mitochondrion's matrix to the intermembrane space. Due to the fact that there are more protons outside the matrix than inside, an active pump creates a gradient of proton concentration across the inner mitochondrial membrane.An electrochemical potential difference that functions similarly to a battery or energy storage unit for the cell is produced by the difference in pH and electric charge (while disregarding variations in buffer capacity). As the process generates potential energy, it can also be compared to cycling uphill or charging a battery for later use. Instead of producing energy, the proton pump creates a gradient that stores energy for later use.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74231 | (R)-Tegoprazan ((R)-CJ-12420; (R)-RQ-00000004) | 942195-56-4 | (R)-Tegoprazan ((R)-CJ-12420; example 3) is a benzimidazole analogue, a potent gastric H+/K+-ATPase inhibitor, and a potent inhibitor of canine kidney Na+/K+-ATPase. |
|
V1634 | Bafilomycin A1 (Baf-A1) | 88899-55-2 | Bafilomycin A1 (formerlyknown as NSC-381866; NSC381866;NSC 381866) is a novel, potent and selective inhibitor of vacuolar H+-ATPase (V-ATPases) with antibacterial activity. |
|
V74232 | Caloxin 2A1 | 350670-85-8 | Caloxin 2A1 is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. |
|
V77169 | Caloxin 2A1 TFA | Caloxin 2A1 TFA is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. | |
|
V1638 | Dexlansoprazole (R-Lansoprazole) | 138530-94-6 | Dexlansoprazole (formerly known as T168390; TAK390;Kapidex;Dexilant,R-Lansoprazole and TAK-390MR), the dextrorotatory or R-enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties byemploying a novel release formulation that prolongs its absorption. |
|
V51196 | Dexrabeprazole sodium | 171440-18-9 | R-enantiomer of Rabeprazole Sodium, PPI |
|
V33616 | Esomeprazole magnesium | 1198768-91-0 | Esomeprazole magnesium, the magnesium salt of esomeprazole, is a potent proton pump inhibitor (PPI) with potential usefulness in thetreatment of gastroesophageal reflux disease-GERD. |
|
V1635 | Esomeprazole magnesium (S-Omeprazole magnesium) | 161973-10-0 | Esomeprazole Magnesium (S-Omeprazole magnesium; Nexium; H 168/68), the magnesium salt of esomeprazole, is S-isomer of omeprazole which is a proton pump inhibitor (PPI) that has been approved for reducing gastric acid secretion (e. |
|
V31594 | Esomeprazole Magnesium trihydrate | 217087-09-7 | Esomeprazole Magnesium trihydrate (S-Omeprazole magnesium trihydrate) is a proton pump inhibitor (PPI) that is usedto reduce gastric acid secretion. |
|
V22465 | Ilaprazole (IY-81149) | 172152-36-2 | Ilaprazole (IY81149) is an orally bioavailable anti-ulcer agent, acting as a proton pump inhibitor (PPI) and is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. |
|
V35087 | Ilaprazole sodium (IY-81149 sodium) | 172152-50-0 | Ilaprazole (IY-81149) sodium, an orally bioactive proton pump inhibitor, irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparations. |
|
V35088 | Ilaprazole sodium hydrate (IY-81149 sodium hydrate) | 2322264-11-7 | Ilaprazole (IY-81149) sodium hydrate, an orally bioactive proton pump inhibitor, irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparations. |
|
V1683 | KPT-276 | 1421919-75-6 | This product has been discontinued. |
|
V1632 | Lansoprazole (AG 1749) | 103577-45-3 | Lansoprazole (formerly A65006, AG1749;A-65006, AG-1749; trade name Prevacid, Zoton, Agopton, Bamalite, Opiren),a prescription and OTC drug for treatment for heartburn, is a potent and next generation proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. |
|
V74229 | Linaprazan (Linaprazan; AZD0865) | 248919-64-4 | Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding. |
|
V1633 | Omeprazole (H 16868) | 73590-58-6 | Omeprazole (H-16868; H16868;trade names: Prilosec, Zegerid), approved by the FDA, is available as a prescription and over-the-counter (OTC) drug used as a treatment for frequent heartburn. |
|
V1637 | Pantoprazole (BY1023) | 102625-70-7 | Pantoprazole (BY1023; SKF96022; BY-1023;SKF-96022;Protonix), an approved anti-ulcer drug, is a proton pump inhibitor (PPI) used for short-term treatment of erosion and ulceration of the esophagus caused by GERD (gastroesophageal reflux disease). |
|
V21158 | Pantoprazole Sodium (SKF96022) | 138786-67-1 | Pantoprazole Sodium (BY1023; SKF96022; Protonix) is an anti-ulcer drug that acts as a proton pump inhibitor (PPI) and is used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. |
|
V32396 | Pantoprazole sodium hydrate | 164579-32-2 | Pantoprazole Sodium hydrate (BY1023; SKF96022; Protonix) is an anti-ulcer drug acting as a proton pump inhibitor (PPI) and is used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. |
|
V1639 | PF-3716556 | 928774-43-0 | PF 3716556 (PF3716556; PF-3716556) is a novel, potent and selective P-CAB (potassium-competitive acid blocker: acid pump antagonist) with anti-acid reflux activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
